Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C001 - Comprehensive Approach to Neuromodulators and Fillers in 2018

Thursday, July 26; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify the different types of fillers/neuromodulators and describe their characteristics
  • Locate the plans and sites of injection according to indications
  • Choose the appropriate fillers/toxins while designing treatment strategies


Key subjects to be covered in the session include: " Principles and practices to achieve optimal results for facial shaping, wrinkle reduction and facial rejuvenation using neurotoxins and dermal fillers " Identifying and managing complications arising from neurotoxins/fillers " Overview of off-label indications/techniques and new generation neurotoxins/fillers in the pipeline available and the next generation neurotoxins pending approval " The use of microcannulas " Combining neurotoxins/injectables with energy-based devices " Evidence-based clinical results


  • Alam, Murad, MD: Allergan, Inc – C(Fees); Amway Corporation – C(H); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Pulse Biosciences – C(Fees);
  • Callender, Valerie D., MD: Aclaris Therapeutics Inc. – C(H); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Aerolase – A(H); Allergan, Inc – I(Grants/Research Funding), SP(H); Allergan, Inc. – C(H); Avon Products, Inc. – I(Grants/Research Funding); Cassiopea SpA – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – I(Grants/Research Funding); IntraDerm Pharmaceuticals – A(H); Menlo Therapeutics – A(H); Novan – I(Grants/Research Funding); PCA SKIN – A(H); Pfizer Inc. – SP(H); Promius Pharmaceuticals – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Samumed, LLC – A(H); Sienna Biopharmaceuticals – A(H); Suneva Medical, Inc. – I(Grants/Research Funding); Unilever Home & Personal Care USA – A(H);
  • Dayan, Steven, MD: Allergan, Inc. – I(Grants/Research Funding); AOBiome, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Croma-Pharma GmbH Austria – C(Fees); Eclipse Medical – C(Fees); Galderma Research & Development, LLC – I(Grants/Research Funding); Lumenis – SP(H); Mentor Corporation – I(Grants/Research Funding); Merz Aesthetics – C(Fees); Recros Medica – I(Grants/Research Funding); Revance Therapeutics, Inc. – C(Fees); Stratapharma – C(Grants/Research Funding); Topix Pharmaceuticals, Inc. – I(Grants/Research Funding);
  • Henry, Michelle Fern, MD: no financial relationships exist with commercial interests.
  • Lipner, Shari, MD, PhD: Bako Diagnostics – C(H); MOE Medical Devices LLC – I(Grants/Research Funding);
  • Ortiz, Arisa, MD: Alastin Skincare, Inc – C(H); Allergan, Inc – A(H), SH(NC), SP(H); BTL Industries – O(EQ); Cutera, Inc. – C(H); Guthy-Renker – SP(S); InMode MD Ltd – A(H), SP(H); Merz Aesthetics – A(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Rodan and Fields – A(H); Sciton Inc. – A(H), SP(H); Sienna Biopharmaceuticals – I(Grants/Research Funding); Ulthera – Data Safety Monitoring Board(H);
  • Sadick, Neil S., MD: Allergan, Inc. – C(H), O(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Cassiopea SpA – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H), I(Grants/Research Funding); Derm Advance – SH(SO); DS Laboratories – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Hydropeptide, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Neostrata – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Nutraceutical Wellness, LLC. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Prescriber's Choice – O(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Taub, Amy Forman, MD: Allergan, Inc – A(H); Almirall – A(H); Cutera, Inc. – I(EQ), I(Grants/Research Funding); Exeltis – A(H); Hydrafacial – I(EQ), I(Grants/Research Funding); MediCell Technologies LLC – I(Grants/Research Funding), SH(ST); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sterilis Medical Corporation – SH(ST); Suneva Medical, Inc. – Speaker/Faculty Education(H); Swiss American – A(H); Syneron, Inc. – SP(H);
  • Weinstein Velez, Mara C, MD: no financial relationships exist with commercial interests.
  • Wu, Douglas, MD, PhD: Allergan, Inc. – Speaker/Faculty Education(H); Galderma USA – Speaker/Faculty Education(H); Syneron Candela – C(H);
Thursday, July 26
1:00 PM
Wu / Anatomic Considerations for neuromodulators
1:15 PM
Dr. Weinstein Velez / Upper and lower face treatment with neuromodulators
1:30 PM
Dr. Lipner / New uses for neuromodulators
1:45 PM
Dr. Dayan / Anatomic consideration for fillers: avoiding danger zones
2:00 PM
Dr. Alam / Volumetric structural rejuvenation
2:15 PM
Dr. Callender / Periocular and perioral rejuvenation
2:30 PM
Dr. Sadick / Off face use of fillers
2:45 PM
All faculty / Break
3:00 PM
Dr. Henry / The male perspective for fillers/neuromodulators
3:15 PM
Dr. Ortiz / Combining fillers/neuromodulators with energy-based devices
3:30 PM
Dr. Taub / Preventing and managing complications
3:45 PM
All faculty / Panel discussion/Q&A
Event Details
  • Date
    Thursday, July 26
  • Time
    1:00 PM - 4:00 PM
  • Location
    Columbus KL
  • CME Credits
  • Type
  • Amy Forman Taub, MD, FAAD
  • Arisa Ortiz, MD, FAAD
  • Douglas Wu, MD, PhD
  • Mara C Weinstein Velez, MD, FAAD
  • Michelle Fern Henry, MD, FAAD
  • Murad Alam, MD, FAAD
  • Shari Lipner, MD, PhD, FAAD
  • Steven Dayan, MD
  • Valerie D. Callender, MD, FAAD